24价肺炎球菌结合疫苗与推荐肺炎球菌疫苗在老年人中的成本效果与公共卫生影响比较
采用马尔可夫模型比较24价肺炎球菌结合疫苗与美国现行推荐策略及不接种在≥65岁人群中的成本效果与公共卫生影响。24价结合疫苗预防的病例和死亡少于21价结合疫苗,后者在经济上更有利,结果在确定性和概率敏感性分析中稳健。
要点
- 24价结合疫苗预防的肺炎球菌疾病病例和死亡少于21价结合疫苗。
- 成本效果分析中21价结合疫苗较24价及其他策略均经济有利。
- 考虑儿童接种间接效应后上述结果仍稳健。
核心结论
- 在老年人中,24价肺炎球菌结合疫苗与覆盖更多成人致病血清型且较少受儿童接种间接效应影响的21价结合疫苗相比,临床和经济上均不利。
研究设计与样本
- 马尔可夫模型比较24价肺炎球菌结合疫苗与美国现行推荐肺炎球菌疫苗接种策略及不接种,人群为≥65岁老年人。
- 年龄、种族和慢性病特异性肺炎球菌疾病风险及血清型特异性疾病风险来自美国疾病控制与预防中心数据。
- 疫苗效果采用德尔菲专家组和临床试验数据估计,疫苗接种和肺炎球菌疾病成本来自美国数据库。
- 情景分析考察儿童肺炎球菌接种对成人疾病的间接效应,数据收集和分析于2024年进行。
主要发现
- 24价肺炎球菌结合疫苗预防的肺炎球菌疾病病例和死亡少于近期推荐的21价肺炎球菌结合疫苗,后者基于成人肺炎球菌疾病血清型配制。
- 成本效果分析中,无论是否考虑儿童接种的潜在间接效应,21价肺炎球菌结合疫苗均较24价肺炎球菌结合疫苗及所有其他接种策略经济有利。
- 上述发现在确定性和概率敏感性分析中稳健且一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The potential impact of an in-development 24-valent pneumococcal conjugate vaccine compared with that of currently recommended vaccines in older adults is unclear. Similar to most currently available pneumococcal conjugate vaccines, 24-valent pneumococcal conjugate vaccine's formulation is based on childhood pneumococcal disease epidemiology. Decision analysis techniques were used to estimate 24-valent pneumococcal conjugate vaccine cost-effectiveness and public health effects in U.S. older adults. METHODS: A Markov model compared 24-valent pneumococcal conjugate vaccine with currently recommended U.S. pneumococcal vaccination strategies in older adults (aged ≥65 years) and with no vaccination. Age-, race-, and chronic medical condition-specific pneumococcal illness risks and serotype-specific disease risks were obtained from Centers for Disease Control and Prevention data. Vaccine effectiveness was estimated using Delphi panel and clinical trial data. Vaccination and pneumococcal illness costs were from U.S. DATABASES: Scenario analyses examined indirect effects of childhood pneumococcal vaccination on adult disease. Data were collected and analyses were performed in 2024. RESULTS: The 24-valent pneumococcal conjugate vaccine prevented fewer pneumococcal disease cases and deaths than the recently recommended 21-valent pneumococcal conjugate vaccine, which is formulated on the basis of adult pneumococcal disease serotypes. In cost-effectiveness analyses, 21-valent pneumococcal conjugate vaccine was economically favorable compared with 24-valent pneumococcal conjugate vaccine and all other vaccination strategies, both without and with consideration of potential childhood vaccination indirect effects. These findings were robust and consistent with those in deterministic and probabilistic sensitivity analyses. CONCLUSIONS: In older adults, 24-valent pneumococcal conjugate vaccine was clinically and economically unfavorable compared with 21-valent pneumococcal conjugate vaccine, which covers more adult disease-causing pneumococcal serotypes and is less susceptible to childhood vaccination indirect effects.
引用
- Smith KJ, Wateska AR, Nowalk MP, et al. Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults. Am J Prev Med. 2024. PMID: 39615769. doi:10.1016/j.amepre.2024.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。